DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Brands, followed by Regional Brands which are OTC and prescription.

Key Countries

The Czech Republic
Poland
Romania
Russia
Slovakia

The Developing Europe & CIS Injectable thrombosis market was valued at EUR318 million as at March 2020.

Source: IQVIA – March 2020

STATISTICS

Number of products launched:

Nil

(2019: Nil)

Average staff turnover:

20%

(2019: 18%)

Number of product recalls:

Nil

(2019: Nil)

Number of work-related fatalities:

Nil

(2019: Nil)

Number of permanent employees

273

June 2020

264

June 2019

Revenue	2020 R’million	2019 (CER) R’million	Change %
Regional Brands	435	393	11
Sterile Focus Brands	2 116	2 289	(8)
Anaesthetics Brands	174	299	(42)
Thrombosis Brands	1 942	1 990	(2)

Total	2 551	2 682	(5)

Note: Commercial Pharmaceuticals revenue by customer geography.